# US 2024/0199723 A1 · Hyperimmunized egg product for treating or preventing alcoholic liver disease and graft-versus-host disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0199723 A1
- Document ID: US20240199723A1
- Status: Published application
- Kind: A1
- Application number: 18/555,338
- Filed: 2022-04-15
- Published: 2024-06-20
- Earliest claimed: 2021-04-16
- Assignees: Prodigy Biotech
- Applicants: Prodigy Biotech
- Inventors: Subramanian V. Iyer; Sunny Patel
- Web page: https://patentgrep.com/patent/US20240199723A1

## CPC

- A61K 35/57: Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
- C07K 16/02: from eggs
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07K 16/1228: Enterobacterales (O), e.g. Citrobacter (G), Serratia (G), Proteus (G), Providencia (G), Morganella (G) or Yersinia (G)
- A61K 2039/505: {comprising antibodies}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/11: isolated from eggs
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

In one aspect, the present disclosure is directed to a method for preventing or treating alcoholic liver disease or graft-versus-host disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a hyperimmunized egg product obtained from an egg-producing animal, thereby preventing or treating the alcoholic liver disease or the graft-versus-host disease in the subject, wherein the hyperimmunized egg product comprises a therapeutically effective amount of one or more antibodies to an antigen selected from the group consisting of Enterococcus faecalis, Enterococcus faecalis cytolysin toxin, and Enterococcus faecium. The present disclosure is also directed to hyperimmunized eggs and egg products produced by an animal that has been hyperimmunized with an antigen selected from the group consisting of Enterococcus faecalis, isolated Enterococcus faecalis cytolysin toxin, and Enterococcus faecium. Methods of preparing the hyperimmunized eggs and egg products are also disclosed.

## Claims

### Claim 1

A method for preventing or treating alcoholic liver disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a hyperimmunized egg product obtained from an egg-producing animal, thereby preventing or treating the alcoholic liver disease in the subject, wherein the hyperimmunized egg product comprises a therapeutically effective amount of one or more antibodies to an antigen selected from the group consisting of Enterococcus faecalis and Enterococcus faecalis cytolysin toxin.

### Claim 2

A method for preventing or treating graft-versus-host disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a hyperimmunized egg product obtained from an egg-producing animal, thereby preventing or treating the graft-versus-host disease in the subject, wherein the hyperimmunized egg product comprises a therapeutically effective amount of one or more antibodies to an antigen selected from the group consisting of Enterococcus faecalis, Enterococcus faecalis cytolysin toxin, and Enterococcus faecium.

### Claim 3 (depends on 1)

The method of claim 1, wherein the hyperimmunized egg product comprises a therapeutically effective amount of one or more antibodies to Enterococcus faecalis, and a therapeutically effective amount of one or more antibodies to Enterococcus faecalis cytolysin toxin.

### Claim 4 (depends on 1)

The method of claim 1, further comprising hyperimmunizing the egg-producing animal with an antigen selected from the group consisting of Enterococcus faecalis, isolated Enterococcus faecalis cytolysin toxin, and Enterococcus faecium.

### Claim 5 (depends on 4)

The method of claim 4, further comprising collecting a hyperimmunized egg from the egg-producing animal that has been hyperimmunized, and preparing a hyperimmunized egg product from the hyperimmunized egg.

### Claim 6 (depends on 1)

The method of claim 1, wherein the hyperimmunized egg product comprises at least 20% more by weight of an IgY antibody specific to an antigen selected from the group consisting of Enterococcus faecalis, Enterococcus faecalis cytolysin toxin, and Enterococcus faecium relative to a control egg product obtained from an egg-producing animal that is not hyperimmunized.

### Claim 7

(canceled)

### Claim 8 (depends on 1)

The method of claim 1, wherein the hyperimmunized egg product is administered orally or intravenously.

### Claim 9 (depends on 1)

The method of claim 1, wherein administration of the hyperimmunized egg product to the subject reduces the level of Enterococcus faecalis in the subject relative to a subject that is not administered the hyperimmunized egg product.

### Claim 10 (depends on 1)

The method of claim 1, wherein administration of the hyperimmunized egg product to the subject reduces liver injury in the subject relative to a subject that is not administered the hyperimmunized egg product.

### Claim 11 (depends on 1)

The method of claim 1, wherein the subject is a human.

### Claim 12

A hyperimmunized egg produced by an animal that has been hyperimmunized with an antigen selected from the group consisting of Enterococcus faecalis, isolated Enterococcus faecalis cytolysin toxin, and Enterococcus faecium, wherein the level of antibodies to the antigen in the hyperimmunized egg is increased relative to an egg from an animal that has not been hyperimmunized.

### Claim 13 (depends on 12)

The hyperimmunized egg of claim 12, wherein the animal has been hyperimmunized with Enterococcus faecalis and isolated Enterococcus faecalis cytolysin toxin, and wherein the level of antibodies to the Enterococcus faecalis and the isolated Enterococcus faecalis cytolysin toxin is increased relative to an egg from an animal that has not been hyperimmunized.

### Claim 14 (depends on 12)

A hyperimmunized egg product obtained from the hyperimmunized egg of claim 12.

### Claim at position 15

15-16. (canceled)

### Claim 17 (depends on 14)

The hyperimmunized egg product of claim 14, wherein the hyperimmunized egg product is purified or partially purified IgY antibody to Enterococcus faecalis cytolysin toxin.

### Claim 18 (depends on 14)

The hyperimmunized egg product of claim 14, wherein the hyperimmunized egg product is purified or partially purified IgY antibody to Enterococcus faecalis.

### Claim 19 (depends on 14)

The hyperimmunized egg product of claim 14, wherein the hyperimmunized egg product consists of purified or partially purified IgY antibody to Enterococcus faecalis and purified or partially purified IgY antibody to Enterococcus faecalis cytolysin toxin.

### Claim 20 (depends on 14)

A pharmaceutical composition comprising the hyperimmunized egg product of claim 14 and a pharmaceutically acceptable carrier.

### Claim at position 20

21-23. (canceled)

### Claim 24 (depends on 20)

The pharmaceutical composition of claim 20 formulated for oral administration.

### Claim 25 (depends on 24)

The pharmaceutical composition of claim 24, wherein the hyperimmunized egg product is formulated in nanoparticles or in an emulsion.

### Claim 26 (depends on 20)

The pharmaceutical composition of claim 20 formulated for intravenous administration.

### Claim at position 24

27-31. (canceled)
